Drug Profile

Inlexisertib - Deciphera Pharmaceuticals

Alternative Names: DCC 3116

Latest Information Update: 28 Nov 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Deciphera Pharmaceuticals
Developer Deciphera Pharmaceuticals; Pfizer
Class Alkanes; Aniline compounds; Antineoplastics; Fluorinated hydrocarbons; Ketones; Oxazepines; Piperazines; Propylamines; Pyrimidines; Small molecules
Mechanism of Action Autophagy-related protein-1 homolog inhibitors; Ulk2 protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I/II Gastrointestinal stromal tumours; Solid tumours
Discontinued Colorectal cancer

Most Recent Events

28 Nov 2025 Chemical structure information added.
19 Jul 2024 3863954 - no updates
11 Jun 2024 Deciphera Pharmaceuticals has been acquired by Ono Pharmaceutical

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com